It's that time of year again: the dreaded cold and flu season is on the horizon. But lurking in the shadows is a more ...

The truth is 80% of babies under 1 year old catch RSV. “They probably mostly catch it from other children,” said Andrew Pavia, MD, Pediatric Infectious Disease at University of Utah Health/Primary ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

The recommendations are not overkill, says a pharmacist. “We’re seeing a lot of patients ... that have respiratory illness ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...

Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.

Ahead of flu season, the Indy recorder sat down with Dr. Varon Cantrell to discuss which vaccines are right for Hoosiers.

Growing up in Amsterdam, The Netherlands, Louis Bont's father who worked at the Netherlands Cancer Institute (NKI), often ...